Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, VANN-OJUEKAIYE, KENDRA RAYCHELL, who is also the busiest examiner for the company. The prosecution is localized within 1 distinct art unit, focusing the current workload on a single technical specialty. With 1 pending office action and 1 distinct examiner, the company's active portfolio is handled exclusively by VANN-OJUEKAIYE, KENDRA RAYCHELL.
The busiest examiner pending count of 1 matches the total pending office actions, confirming that no other examiners are currently involved. Practitioners should note that the lack of multiple distinct art units or examiners means there is no variation in the current review process. The outcome of this 1 pending office action will determine the immediate success of the company's prosecution in the Biotechnology & Pharmaceuticals area. This 1 distinct examiner is the sole point of contact for the company's current applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253687 | USE OF MATURE MITOCHONDRIAL TRANSCRIPTION FACTOR A (TFAM) FOR DIAGNOSING ORGAN DYSFUNCTIONS | VANN-OJUEKAIYE, KENDRA RAYCHELL | 29d |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253687 | USE OF MATURE MITOCHONDRIAL TRANSCRIPTION FACTOR A (TFAM) FOR DIAGNOSING ORGAN DYSFUNCTIONS | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Final Rejection | 29d | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversitätsklinikum Knappschaftskrankenhaus Bochum GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kendra Raychell Vann-Ojuekaiye has the most, with 1 of Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
